- Current report filing (8-K)
29 11월 2011 - 9:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 29, 2011
OraSure Technologies, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-16537
|
|
36-4370966
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
220 East First Street
Bethlehem, Pennsylvania
|
|
18015-1360
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: 610-882-1820
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On November 29, 2011, the Company issued a press release announcing the receipt from the U.S. Food and Drug Administration of a
waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) for the Companys
OraQuick
®
HCV rapid antibody test. A copy of the press release is attached as Exhibit 99 to this Form 8-K and is
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99
|
|
Press Release, dated November 29, 2011, announcing receipt of a CLIA waiver for the Companys OraQuick
®
HCV rapid antibody test.
|
Signatures
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
O
RA
S
URE
T
ECHNOLOGIES
, I
NC
.
|
|
|
|
Date: November 29, 2011
|
|
By:
|
|
/s/ Jack E. Jerrett
|
|
|
|
|
Jack E. Jerrett
|
|
|
|
|
Senior Vice President, General Counsel and Secretary
|
Index to Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99
|
|
Press Release, dated November 29, 2011, announcing receipt of a CLIA waiver for the Companys OraQuick
®
HCV rapid antibody test.
|
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024